[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Turan T, Yıldırım BA, Tulunay G, Boran N, Yıldız F, Köse MF: Experience in stage IB2 cervical cancer and review of treatment. J Turk Ger Gynecol Assoc; 2010;11(1):27-37

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience in stage IB2 cervical cancer and review of treatment.
  • OBJECTIVE: The aim of the study is to evaluate and compare the efficacy of neoadjuvant chemotherapy (NACT), radical hysterectomy (RH) and radiotherapy (RT) in the treatment of stage IB2 cervical cancer.
  • MATERIAL AND METHODS: Medical records of 86 patients with stage IB2 cervical cancer between 1993 and 2006 were evaluated.
  • However, the mean age of the patients was higher in the RT group and nonsquamous type cervical cancer was more frequent in the RH group.
  • There is need for additional prospective studies comparing multimodal treatment regimens in stage IB2 cervical cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24591891.001).
  • [ISSN] 1309-0399
  • [Journal-full-title] Journal of the Turkish German Gynecological Association
  • [ISO-abbreviation] J Turk Ger Gynecol Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC3939302
  • [Keywords] NOTNLM ; Cervical cancer / neoadjuvant chemotherapy / radical hysterectomy / radiotherapy
  •  go-up   go-down


2. Zivanovic O, Alektiar KM, Sonoda Y, Zhou Q, Iasonos A, Tew WP, Diaz JP, Chi DS, Barakat RR, Abu-Rustum NR: Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy. Gynecol Oncol; 2008 Nov;111(2):265-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy.
  • OBJECTIVE: The treatment of FIGO stage IB2 cervical cancer is controversial.
  • Our aim was to assess treatment patterns, outcomes, and complications in patients with stage IB2 cervical cancer.
  • METHODS: A retrospective study of patients with stage IB2 cervical carcinoma at a single institution between January 1982 and September 2006 was performed.
  • CONCLUSION: Both RH and definitive RT/CRT are adequate management strategies for patients with FIGO stage IB2 cervical cancer.
  • [MeSH-major] Uterine Cervical Neoplasms / therapy


3. Ryu HS, Kang SB, Kim KT, Chang KH, Kim JW, Kim JH: Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea: results of a multicenter retrospective Korean study (KGOG-1005). Int J Gynecol Cancer; 2007 Jan-Feb;17(1):132-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea: results of a multicenter retrospective Korean study (KGOG-1005).
  • The purpose of this study is to review FIGO stage IB2 cervical cancers in Korea for the past 10 years, and evaluate the most frequently employed and appropriate management strategy, and also assess the survival benefits of neoadjuvant chemotherapy (NAC).
  • This is a retrospective chart review of 727 FIGO stage IB2 patients from 1995 to 2005.
  • The most frequently employed primary treatment modality for stage IB2 cervical cancer in Korea during the past 10 years was radical hysterectomy (RH).
  • For FIGO stage IB2 cervical cancer during the past 10 years in Korea, RH and adjuvant RT or CCRT was the most frequently employed treatment strategy.
  • [MeSH-major] Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy


Advertisement
4. Loizzi V, Cormio G, Vicino M, Selvaggi L: Neoadjuvant chemotherapy: an alternative option of treatment for locally advanced cervical cancer. Gynecol Obstet Invest; 2008;65(2):96-103
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy: an alternative option of treatment for locally advanced cervical cancer.
  • Although the incidence of cervical cancer has declined in both North America and Europe, it still represents the second most common cancer in women and the fifth most common malignancy worldwide.
  • Most patients in the developed countries present with disease either confined to the cervix or with limited extension beyond it.
  • In 1999, five randomized clinical trials performed by the Gynecologic Oncology Group, the Radiation Therapy Oncology Group and the Southwest Oncology Group have demonstrated a significant outcome advantage when cisplatin-based chemotherapy was administered during radiation in patients with cervical cancer.
  • In the current review, we will analyze the role of neoadjuvant chemotherapy followed by radiotherapy and surgery as an alternative option treatment to the standard chemoradiation for locally advanced cervical cancer (stage Ib2 or larger).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoadjuvant Therapy. Uterine Cervical Neoplasms

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 17878736.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 63
  •  go-up   go-down


5. Hoh JK, Choi JS, Lee JH, Lee KW, Han JS, Lee EJ: Repeat laparoscopic paraaortic lymphadenectomy for an isolated lymph node recurrence in a patient with stage IB2 cervical cancer. J Minim Invasive Gynecol; 2009 Nov-Dec;16(6):781-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeat laparoscopic paraaortic lymphadenectomy for an isolated lymph node recurrence in a patient with stage IB2 cervical cancer.
  • We report a case of repeat laparoscopic paraaortic lymphadenectomy (LPAL) after surgery and concurrent chemoradiation of cervical cancer, FIGO stage IB2.
  • Repeat LPAL is thus a feasible and effective procedure to remove and confirm of an isolated paraaortic lymph node recurrence after previous surgery and chemoradiation for treating cervical cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Laparoscopy / methods. Lymph Node Excision / methods. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19896611.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Lachance JA, Darus CJ, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA: A cost comparison of two strategies for treating stage IB2 cervical cancer. Int J Gynecol Cancer; 2008 Mar-Apr;18(2):274-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cost comparison of two strategies for treating stage IB2 cervical cancer.
  • Patients with stage IB2 cervical cancer at our institution are treated primarily with definitive chemoradiation, or chemoradiation followed by adjuvant hysterectomy.
  • We identified all patients with stage IB2 cervical cancer who received their entire treatment regimen at our institution between 1995 and 2004.
  • We identified 46 patients with stage IB2 cervical cancer, 23 who received a second brachytherapy procedure and 23 who underwent simple hysterectomy.
  • We conclude that definitive chemoradiation appears to be associated with lower costs for management of stage IB2 cervical cancer when compared to simple adjuvant hysterectomy.
  • [MeSH-major] Antineoplastic Agents / economics. Hysterectomy / economics. Radiotherapy / economics. Uterine Cervical Neoplasms / economics. Uterine Cervical Neoplasms / therapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334009.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Rocconi RP, Estes JM, Leath CA 3rd, Kilgore LC, Huh WK, Straughn JM Jr: Management strategies for stage IB2 cervical cancer: a cost-effectiveness analysis. Gynecol Oncol; 2005 May;97(2):387-94
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management strategies for stage IB2 cervical cancer: a cost-effectiveness analysis.
  • OBJECTIVE: To assess the potential effectiveness and medical costs of three common strategies to manage Stage IB2 squamous cell carcinoma of the cervix (CXCA).
  • METHODS: A decision analysis model compared three strategies to manage Stage IB2 CXCA:.
  • CONCLUSIONS: RHYST is the most cost-effective strategy to manage Stage IB2 CXCA and would be favored in settings where resources are limited.
  • [MeSH-major] Carcinoma, Squamous Cell / economics. Carcinoma, Squamous Cell / therapy. Uterine Cervical Neoplasms / economics. Uterine Cervical Neoplasms / therapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863134.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Magrina JF, Kho R, Montero RP, Magtibay PM, Pawlina W: Robotic extraperitoneal aortic lymphadenectomy: Development of a technique. Gynecol Oncol; 2009 Apr;113(1):32-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To develop a robotic technique for extraperitoneal aortic lymphadenectomy in cadavers followed by application in a patient with advanced cervical cancer.
  • The resulting technique was applied to a patient with cervical cancer Stage IB2 presenting with enlarged aortic nodes.
  • [MeSH-major] Lymph Node Excision / methods. Lymph Nodes / surgery. Robotics / methods. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19157527.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Jewell EL, Kulasingam S, Myers ER, Alvarez Secord A, Havrilesky LJ: Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis. Gynecol Oncol; 2007 Dec;107(3):532-40
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis.
  • OBJECTIVES: To estimate the relative cost-effectiveness of treatments for patients with FIGO stage IB2 cervical cancer and no evidence of metastasis as determined by combination of positron emission tomography/computed tomography (PET/CT).
  • Five-year survival estimates for FIGO stage IB2 cervical cancer were obtained from literature.
  • CONCLUSIONS: RH+TA is potentially cost effective when compared to CR for patients with stage IB2 cervical cancer without metastatic disease by PET/CT imaging.
  • [MeSH-major] Uterine Cervical Neoplasms / economics. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17900674.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Termrungruanglert W, Tresukosol D, Vasuratna A, Sittisomwong T, Lertkhachonsuk R, Sirisabya N: Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2. Gynecol Oncol; 2005 May;97(2):576-81
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2.
  • OBJECTIVES: This study aimed to evaluate the efficacy and toxicity of gemcitabine in combination with cisplatin as neoadjuvant therapy in patients with cervical carcinoma stage IB2.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with histologic diagnosis of squamous cell cervical carcinoma staged as IB2 were treated with 2 cycles of cisplatin (70 mg/m(2) on day 1) and gemcitabine (1000 mg/m(2) on days 1 and 8), given every 21 days.
  • CONCLUSION: Neoadjuvant treatment with gemcitabine/cisplatin combination for patients with cervical cancer (stage IB2) appears encouraging, with manageable and acceptable toxicity profile.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Deoxycytidine / analogs & derivatives. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery


11. Mandić A, Novaković P, Erak M, Vitorović S, Zikić D, Nincić D: Stage IB2 cervical cancer: brachytherapy followed by radical hysterectomy. J BUON; 2005 Jul-Sep;10(3):371-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IB2 cervical cancer: brachytherapy followed by radical hysterectomy.
  • PURPOSE: Stage IB2 squamous cell cervical cancer can be treated by radiation therapy alone or by radical hysterectomy and lymphadenectomy (pelvic-/+para-aortic).
  • PATIENTS AND METHODS: During the period January 1994-January 2004, 114 patients with stage IB2 cervical cancer were treated with preoperative brachytherapy followed by radical hysterectomy (Piver class III) with pelvic lymphadenectomy.
  • RESULTS: Histology showed that 56 (49%) patients were without cervical malignant disease.
  • In 58 (51%) patients cervical cancer still existed after brachytherapy and among them 26 (45%) were with lymph node metastasis.
  • Patients with residual cervical carcinoma and positive lymph nodes after brachytherapy were older than those with no residual carcinoma and negative lymph nodes.
  • CONCLUSION: Women with stage IB2 squamous cell cervical cancer primarily treated with brachytherapy must be assessed by appropriate diagnostic procedures to evaluate local effects of brachytherapy and the status outside the pelvis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357191.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Tangsiriwatthana T, Chumworathayi B, Yuenyao P, Luanratanakorn S, Pattamadilok J: Srinagarind Hospital experience in concurrent chemoradiation for 100 patients with stage IB2 to IVA uterine cervical cancer. Radiat Med; 2007 Dec;25(10):502-10
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Srinagarind Hospital experience in concurrent chemoradiation for 100 patients with stage IB2 to IVA uterine cervical cancer.
  • PURPOSE: The aim of this study was to determine responses, acute adverse effects, and survival outcomes of women with stage IB2 to IVA treated with weekly cisplatin concurrent with pelvic irradiation at Srinagarind Hospital.
  • MATERIALS AND METHODS: The medical records of 100 women with cervical cancer stage IB2 to IVA who were treated with weekly cisplatin 40 mg/m(2) concurrent with pelvic radiotherapy at Srinagarind Hospital between January 2003 and June 2006 were reviewed and analyzed.
  • Distribution according to International Federation of Gynecology and Obstetrics (FIGO) staging was IB2 1.0%, IIB 47.0%, IIIB 51.0%, and IVA 1.0%, respectively.
  • CONCLUSION: Weekly cisplatin (40 mg/m(2)) concurrent with pelvic irradiation for locally advanced cervical cancer was effective with acceptable toxicity in Thai women.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy


13. Miller ES, Hoekstra AV, Hurteau JA, Rodriguez GC: Cardiac metastasis from poorly differentiated carcinoma of the cervix: a case report. J Reprod Med; 2010 Jan-Feb;55(1-2):78-80
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac metastasis from poorly differentiated carcinoma of the cervix: a case report.
  • BACKGROUND: Disease metastatic to the heart from cervical carcinoma is rare and associated with a poor prognosis.
  • CASE: A woman presented with stage Ib2 cervical cancer metastatic to the tricuspid valve.
  • Endomyocardial biopsy confirmed metastatic disease consistent with a cervical primary.
  • CONCLUSION: Cervical cancer metastatic to the heart is rare and associated with a poor prognosis.
  • [MeSH-major] Carcinoma / secondary. Heart Neoplasms / secondary. Tricuspid Valve / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20337214.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Darus CJ, Callahan MB, Nguyen QN, Pastore LM, Schneider BF, Rice LW, Jazaeri AA: Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma. Int J Gynecol Cancer; 2008 Jul-Aug;18(4):730-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma.
  • The optimal treatment strategy for stage IB2 cervical carcinoma that maximizes survival while minimizing toxicity remains controversial.
  • The purpose of this study was to compare survival and toxicity in stage IB2 cervical cancer patients treated with chemoradiation and adjuvant extrafascial hysterectomy (cRT + H) versus definitive chemoradiation (cRT).
  • Data were abstracted from patients with IB2 cervical carcinoma primarily treated at a single institution from January 1994 to December 2004.
  • These data complement published results of Gynecologic Oncology Group studies in patients with IB2 cervical cancer.
  • [MeSH-major] Carcinoma / radiotherapy. Carcinoma / surgery. Hysterectomy / methods. Radiation-Sensitizing Agents / therapeutic use. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17949426.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents
  •  go-up   go-down


15. Barranger E, Coutant C, Cortez A, Uzan S, Darai E: Sentinel node biopsy is reliable in early-stage cervical cancer but not in locally advanced disease. Ann Oncol; 2005 Aug;16(8):1237-42
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy is reliable in early-stage cervical cancer but not in locally advanced disease.
  • BACKGROUND: Sentinel lymph node (SN) biopsy based on dual labeling with blue dye and radiocolloid can reliably determine lymph node status in early-stage cervical cancer, but few data are available on its accuracy in more advanced disease.
  • We examined the influence of tumor stage on the accuracy of SN biopsy in patients with cervical cancer.
  • METHODS: Between July 2001 and June 2004, 33 patients (mean age 52 years) with early-stage or locally advanced cervical cancer underwent laparoscopic SN biopsy based on dual labeling with patent blue and radiocolloid.
  • Patients with early-stage cervical cancer (stages IA and IB1, 23 patients) underwent complete laparoscopic pelvic lymphadenectomy after the SN procedure.
  • Patients with locally advanced cervical cancer (stage IB2, IIA or IIB, 10 patients) underwent laparoscopic pelvic and para-aortic lymphadenectomy after SN biopsy and prior neoadjuvant concomitant chemoradiotherapy.
  • The SN identification rates and false-negative rates of patients with early-stage and locally advanced disease were compared.
  • RESULTS: The mean numbers of SNs identified per patient with early-stage and locally advanced cervical cancer were 2.3 (range 0-4) and 1.9 (range 0-4), respectively.
  • SNs were identified in 86.9% (20/23) of patients with early-stage disease and in 80% (8/10) of patients with locally advanced disease.
  • The false-negative rate per patient was zero in early-stage disease and 20% (1/5) in locally advanced disease (no significant difference).
  • When the side of dissection was taken into account, the false-negative rate improved to 42.9% (3/7) in patients with locally advanced disease and remained at zero in early-stage disease (P=0.038).
  • Isolated blue dye was taken up in 53.3% of SNs in patients with locally advanced disease, compared with only 6.4% in patients with early-stage disease.
  • CONCLUSIONS: This study suggests that the SN biopsy technique with dual labeling is less accurate in locally advanced cervical cancer than in early-stage cervical cancer.


17. Xiao Y, Li JD, Shi HL, Liu JH, Feng YL, Li MD: [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer]. Ai Zheng; 2007 Apr;26(4):386-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
  • BACKGROUND & OBJECTIVE: In recent years, the neoadjuvant chemotherapy for cervical cancer has evoked more and more attention and has been used widely.
  • This study was to investigate the chemosensitivity of cervical cancer cells to antitumor drugs using in vitro MTT assay chemosensitivity test.
  • METHODS: The sensitivity of fresh human cervical cancer cells from 32 patients to 9 cytotoxic drugs was tested using in vitro MTT assay.
  • RESULTS: The cytotoxic activities of the 9 drugs for cervical cancer were in sequence from high to low as follows: liposomal paclitaxel, taxol, carboplatin (CBP), ifosfamide (IFO), etoposide (VP-16), 5-fluorouracil (5-FU), cisplatin (DDP), bleomycin (BLM), and cyclophosphamide (CTX).
  • Generally, cervical cancer cells were more sensitive to paclitaxel, taxol, and CBP than to other drugs (P<0.05) with inhibition rates of 56.56%, 55.66%, and 46.81%, respectively.
  • Stage Ib1 cervical cancer cells were more sensitive to taxol, paclitaxel, and CBP than to other drugs with inhibition rates of 58.71%, 53.00%, and 49.25%, respectively; stage Ib2 cervical cancer cells were more sensitive to paclitaxel and taxol than to other drugs with inhibition rates of 65.26% and 50.06%.
  • Both moderately and poorly differentiated squamous cell cancer cells were more sensitive to taxol, paclitaxel, and CBP than to other drugs with inhibition rates of 52.01%, 49.21%, and 40.02% for the former, and 60.02%, 61.16%, and 48.75% for the latter.
  • CONCLUSIONS: MTT assay, a sensitive and widely used chemosensitivity testing method, is helpful in sensitive drug screening and neoadjuvant chemotherapy regimen selection for cervical cancer.
  • Cervical cancer cells are more sensitive to paclitaxel, taxol, and CBP than to other tested drugs in this study.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Squamous Cell / pathology. Cell Survival / drug effects. Uterine Cervical Neoplasms / pathology






Advertisement